Dr Ian Chau holds the position of consultant medical oncologist within the Gastrointestinal and Lymphoma Units at Royal Marsden Hospital and Reader at the Institute of Cancer Research, London & Surrey, UK. He qualified from the United Medical & Dental Schools of Guy’s and St. Thomas’ Hospitals, University of London, before undergoing medical oncology specialist training and clinical research fellowship at the Royal Marsden Hospital. He is the chief or principal investigator of multiple phase I, II and III clinical trials evaluating novel treatment strategies and agents in various cancer signalling pathways. He serves or has served on American Society of Clinical Oncology (ASCO) Scientific Program Committee, ASCO Education Committee, European Society of Medical Oncology (ESMO) Congress Steering Committee, ESMO Asia Scientific Programme and Steering Committee, ESMO Educational Committee and UK National Cancer Research Institute (NCRI) Colorectal Cancer and Pancreatic Cancer Clinical Study Groups, He was the track leaders for Gastrointestinal (non-colorectal) Cancer for ASCO Annual Meeting Education Committee and ESMO Scientific Committee as well as Scientific Chairman for ESMO Asia Congress in 2019. He is on the Trial Management Groups and Trial Steering Groups of multiple national and global phase II-III gastrointestinal cancer and lymphoma trials. He serves or has served on the UK National Institute of Health and Care Excellence (NICE) Clinical Guideline Development Group for non-Hodgkin’s Lymphoma, ASCO Expert Panel for the Management of Immunotherapy Toxicities Guideline and ESMO Clinical Practice Guidelines for Hepatocellular Carcinoma panel. He is the recipient of Swedish Society of GI Oncology Bengt Glimelius Award 2016, merit awards from ASCO Gastrointestinal Cancer Symposium, The Royal Society of Medicine Section of Oncology Clinical Prize, fellowships from the European School of Oncology and ASCO/AACR/FECS Clinical Cancer Research Workshop. He has given invited lectures in over 30 countries. He has served on international drug development advisory boards and has peer review publications in the New England Journal of Medicine, The Lancet, The Lancet Oncology, Journal of Clinical Oncology and other leading oncology / biomedical journals.
Last update: February 2022